By a News Reporter-Staff News Editor at Clinical Trials Week -- Researchers detail new data in Oncology. According to news reporting originating in Seattle, Washington, by NewsRx journalists, research stated, "Antibodies have created high expectations for effective yet tolerated therapeutics in acute myeloid leukemia (AML). Hitherto the most exploited target is CD33, a myeloid differentiation antigen found on AML blasts in most patients and, perhaps, leukemic stem cells in some."
The news reporters obtained a quote from the research from the University of Washington, "Treatment efforts have focused on conjugated antibodies, particularly gemtuzumab ozogamicin (GO), an anti-CD33 antibody carrying a toxic calicheamicin-gamma(1) derivative that, after intracellular hydrolytic release, induces DNA strand breaks, apoptosis, and cell death. Serving as paradigm for this strategy, GO was the first anti-cancer immunoconjugate to obtain regulatory approval in the U. S. While efficacious as monotherapy in acute promyelocytic leukemia (APL), GO alone induces remissions in less than 25-35% of non-APL AML patients. However, emerging data from well controlled trials now indicate that GO improves survival for many non-APL AML patients, supporting the conclusion that CD33 is a clinically relevant target for some disease subsets."
According to the news reporters, the research concluded: "It is thus unfortunate that GO has become unavailable in many parts of the world, and the drug's usefulness should be reconsidered and selected patients granted access to this immunoconjugate."
For more information on this research see: Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. Frontiers in Bioscience-Landmark, 2013;18():1312-1335. Frontiers in Bioscience-Landmark can be contacted at: Frontiers In Bioscience Inc, 16471 Scientific Way, Irvine, CA 92618, USA (see also Oncology).
Our news correspondents report that additional information may be obtained by contacting A.J. Cowan, University of Washington, Dept. of Epidemiol, Seattle, WA 98195, United States. Additional authors for this research include G.S. Laszlo, E.H. Estey and R.B. Walter.
Keywords for this news article include: Antibodies, Seattle, Therapy, Oncology, Washington, Hematology, Immunology, United States, Blood Proteins, Immunoproteins, Nanotechnology, Immunoglobulins, Serum Globulins, Immunoconjugates, Emerging Technologies, Acute Myeloid Leukemia, North and Central America, Clinical Trials and Studies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC